journeylogo (1).jpg
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
March 18, 2024 08:30 ET | Journey Medical Corporation
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
March 13, 2024 07:55 ET | Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023 06:30 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
July 30, 2021 - ROSEN LOGO.jpg
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 24, 2023 16:10 ET | The Rosen Law Firm PA
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM) of...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:17 ET | Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
July 17, 2023 09:00 ET | Elevar Therapeutics
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to elevating...
Growth Report: Pre-Clinical CROs Market Worth $8.41 Billion, Worldwide Driven by Increasing Number of Clinical Trials During (2019-2027) | The Insight Partners
June 29, 2023 09:20 ET | The Insight Partners
Pune, India, June 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners’ latest study on "Pre Clinical CROs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Service, End...
HPQ Silica Polvere Inc. signe un accord de non-divulgation avec un important fabricant de silice pyrogénée
May 25, 2023 08:00 ET | Ressources HPQ Silicium inc.
MONTRÉAL, 25 mai 2023 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), une entreprise technologique spécialisée dans les procédés...
HPQ Silica Polvere Inc. Signs Non-Disclosure Agreement With Leading Fumed Silica Manufacturer
May 25, 2023 08:00 ET | HPQ Silicon Inc.
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), a technology company specializing in green engineering processes for...
Minerva logo
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023 07:30 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...